Cited 0 times in

Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD).

Authors
 Sang Hoon Han  ;  Jialun Zhou  ;  Suneeta Saghayam  ;  Sasheela Vanar  ;  Nittaya Phanuphak  ;  Yi-Ming A Chen  ;  Thira Sirisanthana  ;  Somnuek Sungkanuparph  ;  Christopher KC Lee  ;  Sanjay Pujari  ;  Patrick CK Li  ;  Shinichi Oka  ;  Vonthanak Saphonn  ;  Fujie Zhang  ;  Tuti Parwati Merati  ;  Matthew G Law  ;  Jun Yong Choi 
Citation
 ENDOCRINE JOURNAL, Vol.58(6) : 475-484, 2011 
Journal Title
ENDOCRINE JOURNAL
ISSN
 0918-8959 
Issue Date
2011
MeSH
Adult ; Antiretroviral Therapy, Highly Active/adverse effects ; Antiretroviral Therapy, Highly Active/methods ; Asia/epidemiology ; Asian Continental Ancestry Group ; Cohort Studies ; Databases, Factual ; European Continental Ancestry Group ; Female ; HIV Infections/complications ; HIV Infections/drug therapy ; HIV-Associated Lipodystrophy Syndrome/epidemiology* ; HIV-Associated Lipodystrophy Syndrome/etiology* ; Humans ; Male ; Prevalence ; Risk Factors ; Stavudine/adverse effects*
Keywords
Lipodystrophy ; HIV ; Adverse effects ; Combined antiretroviral treatment ; Asia-Pacific
Abstract
The prevalence of and risk factors for lipodystrophy (LD) among patients receiving combined antiretroviral treatment (cART) in the Asia-Pacific region are largely unknown. LD diagnosis was based on the adverse event definition from the US NIH Division of AIDS (2004 version), and only cases with a severity grade of ≥ 3 were included. TAHOD patients who had recently commenced cART with ≥ 3 drugs after 1996 from sites which had ever reported LD were included in the analysis. Covariates for the forward multivariate logistic regression model included demographic variables, CDC disease classification, baseline CD4 and viral load, hepatitis B/C virus co-infection, and regimen and duration of cART. LD was diagnosed in 217 (10.5%) of 2072 patients. The median duration of cART was 3.8 (interquartile range, 2.2-5.3) years [stavudine, 2.0 (1.0-3.5) years; zidovudine, 1.8 (0.6-3.9) years; and protease inhibitors (PI), 2.6 (1.3-4.5) years]. In the multivariate model, factors independently associated with LD included use of stavudine (≤ 2 years vs. no experience: OR 25.46, p<0.001, > 2 years vs. no experience: OR 14.92, p<0.001), use of PI (> 2.6 years vs. no experience: OR 0.26, p<0.001), and total duration of cART (> vs. ≤ 3.8 years: OR 4.84, p<0.001). The use of stavudine was strongly associated with LD in our cohort. Stavudine-sparing cART strategies are warranted to prevent the occurrence of LD in the Asia-Pacific region.
Files in This Item:
T201102770.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Choi, Jun Yong(최준용) ORCID logo https://orcid.org/0000-0002-2775-3315
Han, Sang Hoon(한상훈) ORCID logo https://orcid.org/0000-0002-4278-5198
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/93702
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links